Steven Yukl, MD
Associate Professor In Res
Infectious Diseases
Websites
Publications
- Mechanistic differences underlying HIV latency in the gut and blood contribute to differential responses to latency-reversing agents.
- HSF1 inhibition attenuates HIV-1 latency reversal mediated by several candidate LRAs In Vitro and Ex Vivo.
- Tissue memory CD4+ T cells expressing IL-7 receptor-alpha (CD127) preferentially support latent HIV-1 infection.
- Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay.
- Heterogeneity in HIV and cellular transcription profiles in cell line models of latent and productive infection: implications for HIV latency.
- Disruption of latent HIV in vivo during the clearance of actinic keratosis by ingenol mebutate.
- Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals.
- Gut and blood differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV latency.
- HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing.
- HIV latency is reversed by ACSS2-driven histone crotonylation.
- Anatomic Compartments as a Barrier to HIV Cure.
- HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.
- An Optimized and Validated Method for Isolation and Characterization of Lymphocytes from HIV+ Human Gut Biopsies.
- Differentiating Immune Cell Targets in Gut-Associated Lymphoid Tissue for HIV Cure.
- A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals.
- Impact of Allogeneic Hematopoietic Stem Cell Transplantation on the HIV Reservoir and Immune Response in 3 HIV-Infected Individuals.
- Exploring HIV latency using transcription profiling.
- Assays for precise quantification of total (including short) and elongated HIV-1 transcripts.
- Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy.
- Tissue reservoirs of HIV.
- Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation.
- Site-specific differences in T cell frequencies and phenotypes in the blood and gut of HIV-uninfected and ART-treated HIV+ adults.
- Anatomic Compartments as a Barrier to HIV Cure.
- CD4+ and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells.
- Exogenous and endogenous hyaluronic acid reduces HIV infection of CD4(+) T cells.
- Decreased HIV type 1 transcription in CCR5-?32 heterozygotes during suppressive antiretroviral therapy.
- Advantages of using the QIAshredder instead of restriction digestion to prepare DNA for droplet digital PCR.
- Discordance between peripheral and colonic markers of inflammation during suppressive ART.
- A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells.
- Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers.
- Comparison of HIV DNA and RNA in gut-associated lymphoid tissue of HIV-infected controllers and noncontrollers.
- The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence.
- Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient.
- Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies.
- Role of retroviral restriction factors in the interferon-a-mediated suppression of HIV-1 in vivo.
- Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter.
- CD4+ T cell reconstitution, T cell activation, and memory T cell subset composition in blood and gut of HIV-negative and ART-suppressed HIV-positive patients: implications for HIV persistence in the gut.
- Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.
- Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.
- Novel application of Locked Nucleic Acid chemistry for a Taqman assay for measuring diverse human immunodeficiency virus type 1 subtypes.
- Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity.
- Blood and guts and HIV: preferential HIV persistence in GI mucosa.
- The W(sh), W(57), and Ph Kit expression mutations define tissue-specific control elements located between -23 and -154 kb upstream of Kit.